Last edition
News about "Profit After Tax"
Akums Drugs and Pharmaceuticals Reports 35.4 Percent EBITDA Growth in Q1 FY27
Akums Drugs and Pharmaceuticals starts FY27 on a strong note, reporting robust revenue, EBITDA and PAT growth as its CDMO business continues to drive performance.
Profit After Tax | 11/08/2026 | By News Bureau
Emcure Reports Robust Q1 FY27 Results, PAT Surges 36 Percent
Emcure Pharmaceuticals reported a strong Q1 FY27 with 22.8 percent revenue growth, 36.2 percent higher profit, improved margins, robust performance across key therapies, and over 15 product approvals in global markets.
Profit After Tax | 07/08/2026 | By News Bureau | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy